ChromaTan and Landmark Bio Collaborate on Innovative AAV Production
ChromaTan Inc. and Landmark Bio have teamed up to revolutionize the manufacturing process for adeno-associated virus (AAV), a key player in gene therapy. This collaboration has received a substantial grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to innovate and enhance the production processes associated with AAV-based therapies. This partnership aims to create a scalable, cost-effective, and accessible platform that streamlines the manufacturing and characterization of these important gene therapy vectors.
Advancements in Gene Therapy Manufacturing
The focus of this project lies in developing an intensified production process for AAV, integrating advanced technologies that aim to improve efficiency and reduce costs in the pharmaceutical manufacturing sector. By utilizing ChromaTan’s BioRMB™ technology and specialized Kascade instrumentation, along with Landmark Bio's esteemed expertise in viral vector production, the teams plan to significantly advance the effectiveness of their production capabilities. This means faster production times and lower costs, which are critical to ensuring patients can access life-changing therapies.
Quote from ChromaTan's CEO
Oleg Shinkazh, CEO of ChromaTan, expressed his enthusiasm about the collaboration, stating, "We are excited to collaborate with Landmark Bio, showcasing their capabilities together with ChromaTan's BioRMB as a next-generation purification platform for gene therapy products. This grant will enable development of our advanced manufacturing technology for multiple AAV serotypes, evaluation of their key process variables, as well as manufacturability." This statement highlights the potential impact this project could have on the future of gene therapy.
Collaboration to Drive Innovation
Landmark Bio’s Chief Technology Officer, Gregg Nyberg, Ph.D., commented on the significance of the project, stating, "We believe this technology has the potential to reduce resin costs and improve step recoveries, increasing capacity while lowering the cost of goods and making these groundbreaking treatments more accessible to patients." This reflects the shared commitment of both companies to enhance the manufacturing landscape for advanced therapeutics, especially in the realm of gene therapies.
NIIMBL’s Role in Advancing Biopharmaceuticals
The NIIMBL partnership plays a crucial role in this development, aiming to foster innovation within the biopharmaceutical manufacturing sector. With a goal to develop standards that enable efficient manufacturing, NIIMBL is dedicated to strengthening the U.S. competitiveness through collaborative efforts like these. Such partnerships can lead to significant advancements in AAV vector production, thereby impacting the biopharmaceutical landscape.
About ChromaTan and Landmark Bio
ChromaTan, headquartered in Spring House, is recognized for its cutting-edge technologies that facilitate biomanufacturing process intensification. Their proprietary BioRMB™ technology offers continuous purification processes for a variety of biologic feeds including viral vectors, which are vital for gene therapies.
Landmark Bio, a public benefit limited liability corporation, was founded by academic and industry leaders to accelerate drug development and therapeutic advancements. Their focus on removing barriers in drug development aims to streamline the path for novel therapeutics, enabling greater access for patients. Together, both companies are set to shape the future of biopharmaceutical manufacturing.
Frequently Asked Questions
What is the focus of the collaboration between ChromaTan and Landmark Bio?
The collaboration aims to advance the production process for adeno-associated virus (AAV), enhancing efficiencies and making gene therapies more accessible.
What technologies are being utilized in this project?
The project utilizes ChromaTan's BioRMB™ technology and Kascade instrumentation, in combination with Landmark Bio's expertise in viral vector manufacturing.
What is the importance of the NIIMBL grant?
The NIIMBL grant facilitates the advancement of innovative manufacturing processes for gene therapies, showcasing both companies' commitment to enhancing biopharmaceutical production.
How does this project benefit patients?
This project is designed to lower production costs and improve manufacturing efficiency, ultimately making groundbreaking gene therapies more accessible to patients.
What is the mission of NIIMBL?
NIIMBL aims to accelerate biopharmaceutical innovation and strengthen manufacturing capabilities through collaboration and investment in transformative technologies.
